文献速递疼痛医学

选择性大麻素类药物治疗慢性神经病理性疼痛:系统综述与荟萃分析

Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis.
PubMed 文献 · Anesth Analg · 2017-01-01

该系统综述与荟萃分析纳入11项随机对照试验共1219例慢性神经病理性疼痛患者,比较选择性大麻素(屈大麻酚、大麻隆、纳比西莫)与常规治疗或安慰剂。

要点

  • 选择性大麻素对慢性神经病理性疼痛有统计学显著但临床意义较小的镇痛获益。
  • 选择性大麻素还改善生活质量和睡眠,未报告重大不良事件。

核心结论

  • 选择性大麻素对慢性神经病理性疼痛提供较小的镇痛获益,证据质量中等、推荐强度弱。

研究设计与样本

  • 系统综述与荟萃分析,纳入11项随机对照试验,共1219例患者(选择性大麻素组614例,对照组605例)。
  • 检索MEDLINE、EMBASE等主要数据库至2016年3月11日,比较选择性大麻素(屈大麻酚、大麻隆、纳比西莫)与常规治疗或安慰剂。
  • 采用GRADE方法评估证据确定性。

主要发现

  • 选择性大麻素使用与生活质量和睡眠改善相关,未报告重大不良事件。
  • 纳入研究在报告质量、神经病理性疼痛病因、选择性大麻素类型和剂量方面存在异质性。

临床怎么用

  • 对于慢性神经病理性疼痛患者,选择性大麻素可作为辅助治疗考虑,但需告知患者镇痛获益较小。
  • 使用选择性大麻素时应注意其可能改善生活质量和睡眠,且未报告重大不良事件。

局限性

  • 纳入研究间存在高度异质性(I²=60%),涉及报告质量、疼痛病因、药物类型和剂量。
  • 需要设计良好的大型随机研究进一步评估特定剂量、干预持续时间及对生理和心理功能的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a lack of consensus on the role of selective cannabinoids for the treatment of neuropathic pain (NP). Guidelines from national and international pain societies have provided contradictory recommendations. The primary objective of this systematic review and meta-analysis (SR-MA) was to determine the analgesic efficacy and safety of selective cannabinoids compared to conventional management or placebo for chronic NP. METHODS: We reviewed randomized controlled trials that compared selective cannabinoids (dronabinol, nabilone, nabiximols) with conventional treatments (eg, pharmacotherapy, physical therapy, or a combination of these) or placebo in patients with chronic NP because patients with NP may be on any of these therapies or none if all standard treatments have failed to provide analgesia and or if these treatments have been associated with adverse effects. MEDLINE, EMBASE, and other major databases up to March 11, 2016, were searched. Data on scores of numerical rating scale for NP and its subtypes, central and peripheral, were meta-analyzed. The certainty of evidence was classified using the Grade of Recommendations Assessment, Development, and Evaluation approach. RESULTS: Eleven randomized controlled trials including 1219 patients (614 in selective cannabinoid and 605 in comparator groups) were included in this SR-MA. There was variability in the studies in quality of reporting, etiology of NP, type and dose of selective cannabinoids. Patients who received selective cannabinoids reported a significant, but clinically small, reduction in mean numerical rating scale pain scores (0-10 scale) compared with comparator groups (-0.65 points; 95% confidence interval, -1.06 to -0.23 points; P = .002, I = 60%; Grade of Recommendations Assessment, Development, and Evaluation: weak recommendation and moderate-quality evidence). Use of selective cannabinoids was also associated with improvements in quality of life and sleep with no major adverse effects. CONCLUSIONS: Selective cannabinoids provide a small analgesic benefit in patients with chronic NP. There was a high degree of heterogeneity among publications included in this SR-MA. Well-designed, large, randomized studies are required to better evaluate specific dosage, duration of intervention, and the effect of this intervention on physical and psychologic function.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Meng H, Johnston B, Englesakis M, et al. Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesth Analg. 2017. PMID: 28537982. doi:10.1213/ANE.0000000000002110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。